Trial · NCT01228903

Uric Acid and the Endothelium in CKD

NCT01228903, Not applicable, Completed, University of Colorado, Denver; results first posted 2017-02-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Uric Acid and the Endothelium in CKD. Trials, record NCT01228903. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01228903

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Uric Acid and the Endothelium in CKD
NCT number: NCT01228903
Status: Completed
Phases: Not applicable
Enrollment: 80 participants, actual
Lead sponsor: University of Colorado, Denver
Conditions: Kidney Disease
Interventions: Allopurinol, Placebo
First posted: 2010-10-27
Last updated: 2017-06-28
Results first posted: 2017-02-23

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Endothelial Dependent Dilation From Baseline to Week 12	Baseline and 12 weeks	Change in Endothelial Dependent Dilation measured by Flow Mediated Dilation at baseline and week 12
Secondary	Change in C-reactive Protein From Baseline to Week 12	Baseline and 12 weeks
Secondary	Change in Serum Interleukin-6 From Baseline to Week 12	Baseline and 12 weeks
Secondary	Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12	Baseline and 12 weeks
Secondary	Change in Oxidized Low Density Lipoprotein From Baseline to Week 12	Baseline and 12 weeks
Other	Change in Serum Uric Acid Levels From Baseline to Week 12	Baseline and 12 weeks	Serum uric acid levels were measured both at baseline and after 12 weeks

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Endothelial Dependent Dilation From Baseline to Week 12	Baseline and 12 weeks		% change	MEAN
SECONDARY	Change in C-reactive Protein From Baseline to Week 12	Baseline and 12 weeks		mg/L	MEAN
SECONDARY	Change in Serum Interleukin-6 From Baseline to Week 12	Baseline and 12 weeks		pg/mL	MEAN
SECONDARY	Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12	Baseline and 12 weeks	-4.7	pg/mL	MEAN
SECONDARY	Change in Oxidized Low Density Lipoprotein From Baseline to Week 12	Baseline and 12 weeks		u/L	MEAN
OTHER_PRE_SPECIFIED	Change in Serum Uric Acid Levels From Baseline to Week 12	Baseline and 12 weeks		mg/dL	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Endothelial Dependent Dilation From Baseline to Week 12	Control	0.2	Standard Deviation 4.1	% change
Change in Endothelial Dependent Dilation From Baseline to Week 12	Allopurinol	0.9	Standard Deviation 3.9	% change
Change in C-reactive Protein From Baseline to Week 12	Control	0.7	Standard Deviation 3.4	mg/L
Change in C-reactive Protein From Baseline to Week 12	Allopurinol	00.42	Standard Deviation 9.5	mg/L
Change in Serum Interleukin-6 From Baseline to Week 12	Control	0.15	Standard Deviation 3.1	pg/mL
Change in Serum Interleukin-6 From Baseline to Week 12	Allopurinol	0.37	Standard Deviation 2.7	pg/mL
Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12	Control	-4.7	Standard Deviation 45.8	pg/mL
Change in Monocyte Chemotactic Protein-1 From Baseline to Week 12	Allopurinol	3.6	Standard Deviation 36.7	pg/mL
Change in Oxidized Low Density Lipoprotein From Baseline to Week 12	Control	-0.08	Standard Deviation 11.8	u/L
Change in Oxidized Low Density Lipoprotein From Baseline to Week 12	Allopurinol	-2.97	Standard Deviation 16.4	u/L

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Control	41
Overall Study	STARTED	Allopurinol	39
Overall Study	COMPLETED	Control	36
Overall Study	COMPLETED	Allopurinol	34
Overall Study	NOT COMPLETED	Control	5
Overall Study	NOT COMPLETED	Allopurinol	5

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	gout	Musculoskeletal and connective tissue disorders	Control	1	41
other	gout	Musculoskeletal and connective tissue disorders	Allopurinol	1	39
other	GI discomfort	Gastrointestinal disorders	Control	2	41
other	GI discomfort	Gastrointestinal disorders	Allopurinol	2	39
other	rash	Skin and subcutaneous tissue disorders	Control	2	41
other	rash	Skin and subcutaneous tissue disorders	Allopurinol	0	39
other	Abnormal Liver Function Tests	Hepatobiliary disorders	Control	2	41
other	Abnormal Liver Function Tests	Hepatobiliary disorders	Allopurinol	0	39
other	Thrombocytopenia	Blood and lymphatic system disorders	Control	2	41
other	Thrombocytopenia	Blood and lymphatic system disorders	Allopurinol	1	39

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Control
Total, all-cause mortality	Allopurinol
Total, other adverse events	Control	9	41
Total, other adverse events	Allopurinol	4	39
Total, serious adverse events	Control	0	41
Total, serious adverse events	Allopurinol	1	39

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
32964203	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
K23DK088833	Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKD	JALAL, DIANA I	UNIVERSITY OF COLORADO DENVER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES	2010 to 2014

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Allopurinol vs Control: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01228903

GET https://conductscience.org/api/trials/v1/NCT01228903/registered

API reference For AI assistants